This study will investigate the effect of RANKL inhibition on sarcopenia in terms of physical performance, muscle mass, and muscle strength and also follow up on clinical outcomes including fall rates and mortality as a randomized controlled trial. Here, TNFSF11 is linked to sarcopenia.